Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Nov 5;30(35):105531.
doi: 10.1016/j.jaccas.2025.105531. Epub 2025 Sep 25.

Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold

Jorgo Kostov  1 , Biljana Zafirovska  2 , Sasko Kedev  2
Affiliations
Case Reports

Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold

Jorgo Kostov et al. JACC Case Rep. .

Abstract

Background: To the best of our knowledge, this is the first reported experience of a patient with late thrombosis of previous Absorb (Abbott Vascular) bioresorbable scaffold (BRS) implantation site, treated with second-generation Magmaris (Biotronik) resorbable magnesium scaffold (RMS).

Case summary: A 55-year-old man with a previously implanted Absorb BRS stent presented with a non-ST-elevation myocardial infarction. Coronary angiography showed thrombotic lesion at the BRS stent site. After intravascular optical coherence tomography (OCT) imaging, a decision was made to implant a second-generation RMS stent. OCT follow-up was performed, with excellent long-term results.

Discussion: Randomized controlled trials have connected early BRS implantation to a higher rate of stent thrombosis. In recent years, the newer generation RMS has confirmed a good safety profile and long-term patency. The idea behind this treatment was to assess the novel RMS technology with serial OCT imaging.

Take-home messages: This case adds new options for the treatment of coronary arteries with novel RMS technology. Intravascular imaging with OCT is essential for optimized treatment and follow-up.

Keywords: acute coronary syndrome; cardiovascular disease; imaging; percutaneous coronary intervention; stents.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
First Percutaneous Coronary Intervention on the Circumflex Artery With First-Generation Absorb Bioresorbable Scaffold Stent
Figure 2
Figure 2
Coronary Angiography With Severe Stenosis on the Place of Previously Implanted Absorb Bioresorbable Scaffold Stent
Figure 3
Figure 3
Optical Coherence Tomography Showing Thrombus on the Circumflex Artery
Figure 4
Figure 4
Plaque Morphology
Figure 5
Figure 5
Angiography and Optical Coherence Tomography of Final Result After Resorbable Magnesium Scaffold Implantation
Figure 6
Figure 6
Angiography and Optical Coherence Tomography at 1.5 Years After Resorbable Magnesium Scaffold Implantation
Figure 7
Figure 7
Optical Coherence Tomography at 3.5 Years After Resorbable Magnesium Scaffold Implantation
Visual Summary
Visual Summary
Case Presentation (A) First BRS implantation. (B) Late thrombosis of previously implanted BRS site treated with novel RMS technology. (C) Long-term follow-up with OCT. BRS = bioresorbable scaffold; OCT = optical coherence tomography; RMS = resorbable magnesium scaffold.
See this image and copyright information in PMC

References

    1. Cassese S., Byrne R.A., Juni P., et al. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention. 2018;13(13):1565–1573. - PubMed
    1. Capodanno D., Gori T., Nef H., et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10(10):1144–1153. - PubMed
    1. Cassese S., Byrne R.A., Ndrepepa G., et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387(10018):537–544. - PubMed
    1. Bangalore S., Bezerra H.G., Rizik D.G., et al. The state of the absorb bioresorbable scaffold: consensus from an expert panel. JACC Cardiovasc Interv. 2017;10:2349–2359. - PubMed
    1. Madanchi M., Cioffi G.M., Attinger-Toller A., et al. Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold. Open Heart. 2021;8(2) doi: 10.1136/openhrt-2021-001776. - DOI - PMC - PubMed

Publication types

LinkOut - more resources